Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

The Journal of Affective Disorders is a premier publication in the field of Clinical Psychology and Psychiatry and Mental Health, published by Elsevier. With an impressive impact factor and a consistent ranking in the Q1 category—12th in Clinical Psychology and 40th in Psychiatry and Mental Health—the journal serves as a critical platform for advancing research on affective disorders since its inception in 1979. The journal’s scope encompasses a wide range of topics related to mood disorders, providing researchers, professionals, and students with the latest findings, theoretical developments, and clinical insights. Despite being a non-open-access journal, subscribers benefit from comprehensive access to high-quality, peer-reviewed articles that inform clinical practice and enrich academic discourse. With its commitment to fostering scientific progress, The Journal of Affective Disorders remains instrumental in shaping the future of mental health research and practice.

Indian Journal of Psychiatry (ISSN: 0019-5545, E-ISSN: 1998-3794) is a premier, peer-reviewed academic journal published by WOLTERS KLUWER MEDKNOW PUBLICATIONS. As a leading publication in the field of psychiatry and mental health since its establishment in 1970, the journal has significantly contributed to the advancement of psychiatric research and clinical practice in India and globally. With an impact factor reflecting its robust academic reputation, the journal is categorized under the Q3 quartile in its field for 2023 and ranks #228 out of 567 in the Scopus rankings. This Open Access journal has been providing cutting-edge research insights since 2007, ensuring that access to vital findings and innovative methodologies is available to a wide readership without restrictions. The Indian Journal of Psychiatry is dedicated to the dissemination of quality research, clinical studies, and reviews, aiming to enhance understanding and treatment of mental health disorders. It serves as an essential resource for researchers, practitioners, and students striving to improve mental health outcomes in diverse populations.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.

International Journal of Geriatric Psychiatry, published by Wiley, stands as a premier journal dedicated to advancing the field of mental health in older adults. With an impressive impact factor reflective of its Q1 categorization in both Geriatrics and Gerontology, as well as Psychiatry and Mental Health, this journal addresses the critical intersection of aging and mental health, providing a platform for impactful research from 1986 through 2024. Researchers and professionals will find the journal invaluable, as it offers comprehensive insights into a range of subjects pertinent to geriatric mental health, with its ranking in Scopus highlighting its academic rigor and relevance (Rank #147/567 in Psychiatry and Mental Health; Rank #37/116 in Geriatrics and Gerontology). Though it operates on a traditional subscription model, the journal's significant contributions to the understanding of psychiatric disorders in the elderly make it a key resource for anyone involved in geriatric care and research.

Asia-Pacific Psychiatry is a leading academic journal published by WILEY, focused on the diverse and rapidly evolving fields of psychiatry and mental health within the Asia-Pacific region. With an ISSN of 1758-5864 and an E-ISSN of 1758-5872, this journal has been recognized for its significant impact, holding a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in Psychiatry and Mental Health as of 2023. Its commendable Scopus ranking places it at Rank #83 out of 567 in its category, highlighting its influence and relevance in contemporary research. The journal aims to facilitate the dissemination of high-quality research, reviews, and clinical insights that address mental health challenges, promote global understanding, and encourage collaboration among professionals and academics. Although it is not an open-access journal, the high impact factor underscores its value in the scholarly community, making it an essential resource for researchers, clinicians, and students dedicated to enhancing mental health practices and policies in the region and beyond.

Alpha Psychiatry, published by AVES, stands at the forefront of mental health research and psychiatric advancements. With a commitment to disseminating high-quality and impactful studies, this journal serves as a critical platform for scholars, clinicians, and students interested in exploring the complexities of psychiatric disorders and treatment methodologies. Although the impact factor and specific scope details are still evolving, Alpha Psychiatry is dedicated to fostering interdisciplinary dialogue and promoting innovative research that tackles contemporary challenges in the field of psychiatry. As an open-access journal, it ensures that research is widely accessible, enhancing knowledge transfer and collaboration within the global scientific community. Located in Istanbul, Turkiye, the journal proudly represents a rich academic tradition, aiming to contribute significantly to the global discourse on mental health.

British Journal of Psychiatry, published by Cambridge University Press, stands as a pivotal resource in the realm of mental health and psychiatry. With an impressive impact reflected in its Q1 classifications in both Medicine (miscellaneous) and Psychiatry and Mental Health, this esteemed journal ranks 23rd out of 567 in its field according to Scopus, achieving an exceptional 96th percentile. Since its inception in 1963, the journal has continued to push the boundaries of research and discourse, serving as a platform for groundbreaking studies that enhance our understanding of psychiatric conditions and promote effective therapeutic strategies. Though it does not operate with an open-access model, the British Journal of Psychiatry remains an essential publication for researchers, clinicians, and students alike, offering in-depth insights and innovative findings that are crucial for navigating the complexities of mental health.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.